-
Subject Areas on Research
-
3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).
-
3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis.
-
4-Aminopyridine attenuates muscle atrophy after sciatic nerve crush injury in mice.
-
A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
-
Aspartate release from rat hippocampal synaptosomes.
-
Comment: Is 3,4-DAP a new option in treating MuSK MG?
-
Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine.
-
Exome sequencing detection of two untranslated GFPT1 mutations in a family with limb-girdle myasthenia.
-
Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.
-
In vivo imaging of epileptic activity using 2-NBDG, a fluorescent deoxyglucose analog.
-
Kv3.1b is a novel component of CNS nodes.
-
Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients.
-
Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment.
-
Neocortical disynaptic inhibition requires somatodendritic integration in interneurons.
-
Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia.
-
The histone lysine demethylase Kdm6b is required for activity-dependent preconditioning of hippocampal neuronal survival.
-
Transport pathways in rat lingual epithelium.